CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 87.41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade T2 Biosystems, Inc. - TTOO CFD

1.56
6.59%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.07
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0308 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0308%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0308 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0137%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 1.67
Open* 1.69
1-Year Change* 7.64%
Day's Range* 1.56 - 1.56
52 wk Range 0.0799-0.96
Average Volume (10 days) 10.5843
Average Volume (3 months) 890.529
Market Cap 28.2034
P/E Ratio N/A
Shares Outstanding 352543000
Revenue 27.553
EPS -0.35634
Dividend (Yield %) N/A
Beta 0.50875
Next Earnings Date Nov 2, 2022

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 5, 2022 1.56 -0.10 -6.02% 1.66 1.70 1.54
Dec 2, 2022 1.67 0.01 0.60% 1.66 1.68 1.64
Dec 1, 2022 1.66 0.04 2.47% 1.62 1.69 1.62
Nov 30, 2022 1.64 0.03 1.86% 1.61 1.67 1.61
Nov 29, 2022 1.63 0.02 1.24% 1.61 1.66 1.60
Nov 28, 2022 1.63 -0.10 -5.78% 1.73 1.74 1.58
Nov 25, 2022 1.76 0.08 4.76% 1.68 1.78 1.68
Nov 23, 2022 1.68 0.03 1.82% 1.65 1.69 1.62
Nov 22, 2022 1.67 -0.04 -2.34% 1.71 1.71 1.66
Nov 21, 2022 1.74 -0.04 -2.25% 1.78 1.79 1.73
Nov 18, 2022 1.80 -0.09 -4.76% 1.89 1.90 1.79
Nov 17, 2022 1.88 -0.06 -3.09% 1.94 1.97 1.88
Nov 16, 2022 1.97 -0.04 -1.99% 2.01 2.01 1.93
Nov 15, 2022 2.01 -0.09 -4.29% 2.10 2.30 1.98
Nov 14, 2022 2.20 0.34 18.28% 1.86 2.26 1.86
Nov 11, 2022 1.85 0.11 6.32% 1.74 1.85 1.70
Nov 10, 2022 1.79 0.02 1.13% 1.77 1.80 1.70
Nov 9, 2022 1.73 -0.04 -2.26% 1.77 1.77 1.68
Nov 8, 2022 1.78 -0.02 -1.11% 1.80 1.80 1.71
Nov 7, 2022 1.79 0.07 4.07% 1.72 1.83 1.70

T2 Biosystems, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 4.08 4.666 10.5 8.335 18.13 28.058
Revenue 4.08 4.666 10.5 8.335 18.13 28.058
Cost of Revenue, Total 6.872 12.028 15.404 16.763 20.68 20.703
Gross Profit -2.792 -7.362 -4.904 -8.428 -2.55 7.355
Total Operating Expense 54.958 58.518 55.59 60.393 59.486 71.031
Selling/General/Admin. Expenses, Total 24.077 22.757 25.697 27.304 20.787 28.527
Research & Development 24.009 23.733 14.489 16.326 16.919 21.801
Operating Income -50.878 -53.852 -45.09 -52.058 -41.356 -42.973
Interest Income (Expense), Net Non-Operating -4.098 -8.907 -6.682 -7.348 -5.504 -6.474
Other, Net 0.172 0.331 0.619 0.4 0.062 0.206
Net Income Before Taxes -54.804 -62.428 -51.153 -59.006 -46.798 -49.241
Net Income After Taxes -54.804 -62.428 -51.153 -59.006 -46.798 -49.241
Net Income Before Extra. Items -54.804 -62.428 -51.153 -59.006 -46.798 -49.241
Net Income -54.804 -62.428 -51.153 -59.006 -46.798 -49.241
Total Adjustments to Net Income 0
Income Available to Common Excl. Extra. Items -54.804 -62.428 -51.153 -59.006 -46.798 -49.241
Income Available to Common Incl. Extra. Items -54.804 -62.428 -51.153 -59.006 -46.798 -49.241
Diluted Net Income -54.804 -62.428 -51.153 -59.006 -46.798 -49.241
Diluted Weighted Average Shares 26.0158 32.1315 40.5588 45.5078 121.331 158.861
Diluted EPS Excluding Extraordinary Items -2.10657 -1.94289 -1.26121 -1.29661 -0.3857 -0.30996
Dividends per Share - Common Stock Primary Issue 0 0 0
Diluted Normalized EPS -2.10657 -1.94289 -1.26121 -1.29661 -0.37664 -0.30996
Unusual Expense (Income) 1.1
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total revenue 6.956 6.694 7.428 6.98 7.234
Revenue 6.956 6.694 7.428 6.98 7.234
Cost of Revenue, Total 5.79 4.831 4.72 5.362 6.205
Gross Profit 1.166 1.863 2.708 1.618 1.029
Total Operating Expense 16.658 17.474 19.64 17.259 22.091
Selling/General/Admin. Expenses, Total 6.203 7.244 8.536 6.544 9.23
Research & Development 4.265 5.399 6.384 5.353 6.356
Depreciation / Amortization 0.4 0.3
Operating Income -9.702 -10.78 -12.212 -10.279 -14.857
Interest Income (Expense), Net Non-Operating -1.007 -1.694 -1.913 -1.86 -1.647
Other, Net 0.049 -0.001 0.163 -0.005 0.009
Net Income Before Taxes -10.66 -12.475 -13.962 -12.144 -16.495
Net Income After Taxes -10.66 -12.475 -13.962 -12.144 -16.495
Net Income Before Extra. Items -10.66 -12.475 -13.962 -12.144 -16.495
Net Income -10.66 -12.475 -13.962 -12.144 -16.495
Income Available to Common Excl. Extra. Items -10.66 -12.475 -13.962 -12.144 -16.495
Income Available to Common Incl. Extra. Items -10.66 -12.475 -13.962 -12.144 -16.495
Diluted Net Income -10.66 -12.475 -13.962 -12.144 -16.495
Diluted Weighted Average Shares 148.231 154.885 165.882 166.253 169.855
Diluted EPS Excluding Extraordinary Items -0.07191 -0.08054 -0.08417 -0.07305 -0.09711
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.07191 -0.08054 -0.08417 -0.07305 -0.09711
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 75.438 44.318 56.608 18.895 53.584 44.394
Cash and Short Term Investments 73.488 41.799 50.805 11.033 42.189 32.241
Cash & Equivalents 73.488 41.799 50.805 11.033 16.793 22.245
Total Receivables, Net 0.327 0.467 1.786 2.825 5.099 5.134
Accounts Receivable - Trade, Net 0.327 0.467 1.786 2.825 5.099 5.134
Total Inventory 0.803 1.344 2.677 3.599 3.636 3.909
Prepaid Expenses 0.82 0.708 1.34 1.438 2.66 3.11
Total Assets 89.568 54.861 64.309 28.486 79.078 60.539
Property/Plant/Equipment, Total - Net 13.589 10.015 7.315 9.205 14.805 14.441
Property/Plant/Equipment, Total - Gross 20.655 19.139 18.622 22.441 29.062 29.873
Accumulated Depreciation, Total -7.066 -9.124 -11.307 -13.236 -14.257 -15.432
Other Long Term Assets, Total 0.541 0.528 0.386 0.386 0.687 1.704
Total Current Liabilities 9.885 51.782 52.297 60.572 9.8 11.688
Accounts Payable 0.962 0.648 0.744 3.753 2.058 2.832
Accrued Expenses 4.908 6.218 6.073 11.207 7.512 8.338
Notes Payable/Short Term Debt 0 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 1.269 40.696 42.373 42.902 0
Other Current Liabilities, Total 2.746 4.22 3.107 2.71 0.23 0.518
Total Liabilities 50.23 53.521 52.922 62.491 70.352 73.442
Total Long Term Debt 39.504 1.008 0 0 45.235 47.79
Long Term Debt 39.504 1.008 0 45.235 47.79
Other Liabilities, Total 0.841 0.731 0.625 1.919 15.317 13.964
Total Equity 39.338 1.34 11.387 -34.005 8.726 -12.903
Redeemable Preferred Stock 0 0 0 0 0 0
Common Stock 0.03 0.036 0.044 0.051 0.148 0.166
Additional Paid-In Capital 242.997 267.421 328.514 342.121 431.544 459.151
Retained Earnings (Accumulated Deficit) -203.689 -266.117 -317.171 -376.177 -422.975 -472.216
Total Liabilities & Shareholders’ Equity 89.568 54.861 64.309 28.486 79.078 60.539
Total Common Shares Outstanding 30.4827 35.9489 44.1754 50.6515 148.079 166.401
Short Term Investments 25.396 9.996
Long Term Investments 10.002 0
Other Equity, Total 0.009 -0.004
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 44.587 63.859 54.46 44.394 33.503
Cash and Short Term Investments 33.308 52.788 42.089 32.241 19.386
Cash & Equivalents 10.691 32.708 22.047 22.245 9.397
Short Term Investments 22.617 20.08 20.042 9.996 9.989
Total Receivables, Net 4.034 3.979 4.222 5.134 4.361
Accounts Receivable - Trade, Net 4.034 3.979 4.222 5.134 4.361
Total Inventory 4.525 4.784 4.822 3.909 5.172
Prepaid Expenses 2.72 2.308 3.327 3.11 4.584
Total Assets 70.052 78.898 70.037 60.539 49.039
Property/Plant/Equipment, Total - Net 14.808 14.41 13.865 14.441 14.25
Property/Plant/Equipment, Total - Gross 29.448 29.363 29.028 29.873 29.944
Accumulated Depreciation, Total -14.64 -14.953 -15.163 -15.432 -15.694
Long Term Investments 10.002 0 0 0
Other Long Term Assets, Total 0.655 0.629 1.712 1.704 1.286
Total Current Liabilities 10.401 9.345 11.398 11.688 12.673
Accounts Payable 3.907 2.89 2.616 2.832 3.385
Accrued Expenses 6.094 6.017 8.169 8.338 8.95
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.4 0.438 0.613 0.518 0.338
Total Liabilities 70.618 69.889 72.5 73.442 74.69
Total Long Term Debt 45.855 46.487 47.132 47.79 48.257
Long Term Debt 45.855 46.487 47.132 47.79 48.257
Other Liabilities, Total 14.362 14.057 13.97 13.964 13.76
Total Equity -0.566 9.009 -2.463 -12.903 -25.651
Redeemable Preferred Stock 0 0 0 0
Common Stock 0.148 0.165 0.166 0.166 0.171
Additional Paid-In Capital 432.905 454.95 457.439 459.151 462.9
Retained Earnings (Accumulated Deficit) -433.635 -446.11 -460.072 -472.216 -488.711
Other Equity, Total 0.016 0.004 0.004 -0.004 -0.011
Total Liabilities & Shareholders’ Equity 70.052 78.898 70.037 60.539 49.039
Total Common Shares Outstanding 148.492 165.764 165.968 166.401 171.413
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line -54.804 -62.428 -51.153 -59.006 -46.798 -49.241
Cash From Operating Activities -46.442 -47.718 -40.138 -45.361 -43.215 -38.874
Cash From Operating Activities 2.28 2.94 2.449 2.197 1.71 1.27
Non-Cash Items 5.274 12.194 12.509 9.59 8.411 11.268
Cash Interest Paid 2.732 3.959 3.786 4.659 3.692 3.814
Changes in Working Capital 0.808 -0.424 -3.943 1.858 -6.538 -2.171
Cash From Investing Activities -5.487 -2.476 -0.593 -0.761 -36.261 24.791
Capital Expenditures -5.487 -2.476 -0.593 -0.761 -0.804 -0.46
Other Investing Cash Flow Items, Total 0 0 -35.457 25.251
Cash From Financing Activities 51.755 18.505 49.657 6.35 85.607 20.535
Financing Cash Flow Items 39.338 18.64 49.237 6.65 85.311
Issuance (Retirement) of Stock, Net 1.018 1.059 1.967 0.582 0.296 20.535
Issuance (Retirement) of Debt, Net 11.399 -1.194 -1.547 -0.882 0
Net Change in Cash -0.174 -31.689 8.926 -39.772 6.131 6.452
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -10.66 -23.135 -37.097 -49.241 -16.495
Cash From Operating Activities -8.708 -19.305 -29.032 -38.874 -14.441
Cash From Operating Activities 0.383 0.696 1 1.27 0.286
Non-Cash Items 1.858 4.754 8.492 11.268 3.389
Cash Interest Paid 0.928 2.815 2.815 3.814 1.106
Changes in Working Capital -0.289 -1.62 -1.427 -2.171 -1.621
Cash From Investing Activities 2.553 14.948 14.99 24.791 -0.029
Capital Expenditures -0.197 -0.303 -0.261 -0.46 -0.029
Other Investing Cash Flow Items, Total 2.75 15.251 15.251 25.251 0
Cash From Financing Activities 0.053 20.272 20.296 20.535 1.202
Issuance (Retirement) of Stock, Net 0.053 20.272 20.296 20.535 1.432
Net Change in Cash -6.102 15.915 6.254 6.452 -13.268
Financing Cash Flow Items -0.23

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
475000+

Traders

71000+

Active clients monthly

$51000000+

Monthly investing volume

$30000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

T2 Biosystems, Inc. Company profile

T2 Biosystems, Inc. (TTOO) is an in vitro diagnostics company. It was founded in 2006 and is headquartered in Massachusetts, US.

The company’s product portfolio includes T2Dx Instrument, T2Candida Panel and T2Bacteria Panel, which are powered by its proprietary T2 Magnetic Resonance (T2MR) technology. These technologies enable US Food and Drug Administration (FDA)-cleared blood tests that identify sepsis-causing pathogens without having to wait for blood culture.

Other test or diagnostics services the company offers include T2Resistance to identify carbapenem resistance genes, T2SARS-CoV-2 panel to detect SARS-CoV-2 virus and T2Biothreat to uncover biothreat pathogens. 

The company’s product pipeline covers technologies and products for detecting additional species and antibiotic resistance markers of sepsis pathogens and tests for Lyme disease.

T2Cauris provides detection of the  superbug Candida Auris in patient's skin and blood and hospital environmental samples. T2Lyme can identify the bacteria that cause Lyme disease through a direct-from-blood test panel designed to run on the T2Dx Instrument.

T2 Biosystems, Inc. stock started trading on the NASDAQ stock exchange in 2014 under the ticker symbol TTOO. You can track live TTOO share value and price history at Capital.com.

Industry: Advanced Medical Equipment & Technology (NEC)

101 Hartwell Ave
02421-3125

Income Statement

People also watch

XRP/USD

0.38 Price
-1.730% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 0.00329

BTC/USD

17,062.00 Price
+0.320% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 60.00

US100

11,807.40 Price
+0.130% 1D Chg, %
Long position overnight fee -0.0167%
Short position overnight fee 0.0060%
Overnight fee time 22:00 (UTC)
Spread 1.8

Natural Gas

5.49 Price
-1.970% 1D Chg, %
Long position overnight fee 0.0401%
Short position overnight fee -0.0646%
Overnight fee time 22:00 (UTC)
Spread 0.005

Still looking for a broker you can trust?

Join the 475.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading